
---
title: '美诺华：子公司药品通过仿制药一致性评价'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=8868'
author: 证券时报网
comments: false
date: Thu, 21 Apr 2022 17:35:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=8868'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603538" style="color: #2f67d1;text-decoration: none;" code="603538" target="_blank">美诺华</a>(603538)4月21日晚间公告，公司全资子公司<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603538" style="color: #2f67d1;text-decoration: none;" code="603538" target="_blank">美诺华</a>天康于近日收到国家药监局核准签发的《药品补充申请批准通知书》，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603538" style="color: #2f67d1;text-decoration: none;" code="603538" target="_blank">美诺华</a>天康生产的异烟肼片通过仿制药质量和疗效一致性评价。另外，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603538" style="color: #2f67d1;text-decoration: none;" code="603538" target="_blank">美诺华</a>天康于近日收到国家药监局核准签发的阿哌沙班片《药品注册证书》。</p>

                  
</div>
            